Breaking News Instant updates and real-time market news.

NVS

Novartis

$68.76

-0.2 (-0.29%)

, WBA

Walgreens Boots Alliance

$84.73

-0.8 (-0.94%)

04:55
12/01/16
12/01
04:55
12/01/16
04:55

Forbes Summit Group to hold a summit

Forbes Healthcare Summit is being held in New York on November 30-December 1.

NVS

Novartis

$68.76

-0.2 (-0.29%)

WBA

Walgreens Boots Alliance

$84.73

-0.8 (-0.94%)

SIEGY

Siemens

$112.61

-0.24 (-0.21%)

ESRX

Express Scripts

$75.88

-0.98 (-1.28%)

AGN

Allergan

$194.30

1.66 (0.86%)

IBM

IBM

$162.22

-1.31 (-0.80%)

CELG

Celgene

$118.51

-3.62 (-2.96%)

BMY

Bristol-Myers

$56.44

0.08 (0.14%)

MRK

Merck

$61.19

-1 (-1.61%)

HUM

Humana

$212.64

2.64 (1.26%)

MYL

Mylan

$36.61

0.55 (1.53%)

UTHR

United Therapeutics

$125.61

-0.96 (-0.76%)

PHG

Philips

$28.61

-0.52 (-1.79%)

AXON

Axovant Sciences

$13.53

-0.17 (-1.24%)

GILD

Gilead

$73.70

-1.17 (-1.56%)

PFE

Pfizer

$32.14

0.22 (0.69%)

LLY

Eli Lilly

$67.12

-0.03 (-0.04%)

REGN

Regeneron

$379.24

-8.02 (-2.07%)

  • 01

    Dec

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 06

    Dec

  • 08

    Mar

  • 28

    Mar

  • 29

    Mar

NVS Novartis
$68.76

-0.2 (-0.29%)

11/10/16
ARGS
11/10/16
UPGRADE
ARGS
Buy
Novartis upgraded to Buy from Hold at Argus
11/10/16
11/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Priceline (PCLN) upgraded to Buy from Hold at Stifel while the firm upgraded Expedia (EXPE) to Hold from Sell. 2. IBM (IBM) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan expecting 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. 3. L-3 Communications (LLL) and Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Barclays while the firm upgraded Lockheed Martin (LMT) to Equal Weight from Underweight. 4. Microsoft (MSFT) upgraded to Neutral from Underweight at Atlantic Equities. 5. Novartis (NVS) upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/26/16
LEER
10/26/16
NO CHANGE
Target $80
LEER
Market Perform
Novartis price target lowered to $80 from $89 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Novartis to $80 from $89 after a "disappointing" Q3 performance despite bottom-line beat. The analyst reiterates a Market Perform rating on the shares.
11/30/16
RHCO
11/30/16
NO CHANGE
RHCO
GlycoMimetics has positive read through from deal, says SunTrust
SunTrust analyst Yatin Suneja says that Novartis' (NVS) recent acquisition of Selexys Pharmaceuticals "provides further clinical and commercial validation for the selectin class of adhesion molecules as meaningful therapeutic targets." The analyst notes that the acquisition came after Selexys' SelG1, which utilizes a P-selectin antibody, showed positive Phase II data in sickle cell disease. GlycoMimetics (GLYC) develops selectin antagonists. The analyst expects interest in the name to accelerate as more data is announced. Suneja keeps a Buy rating on the shares.
WBA Walgreens Boots Alliance
$84.73

-0.8 (-0.94%)

11/08/16
JEFF
11/08/16
NO CHANGE
Target $95
JEFF
Buy
Walgreens could benefit from drug pricing pressure, says Jefferies
Jefferies analyst Brian Tanquilut says concerns about the impact of decelerating branded drug price inflation on the pharma supply chain do not necessarily apply to Walgreens Boots Alliance. The company could actually benefit, Tanquilut tells investors in a research note. 85% of the drugs dispensed by Walgreens are generic medications and any semblance of price deflation in that category of drugs should translate into margin expansion opportunities for the company, the analyst contends. He remains bullish on shares of Walgreens with a Buy rating and $95 price target.
11/15/16
LEER
11/15/16
NO CHANGE
Target $85
LEER
Outperform
CVS Health price target lowered to $85 from $105 at Leerink
Leerink analyst David Larsen lowered his price target for CVS Health (CVS) to $85 from $105 as he is incrementally more cautious on the company. Conversely, the analyst is incrementally more positive on Walgreens Boots Alliance (WBA) and believes its deal with Rite Aid (RAD) deal is more likely to go through with Trump as President. Nonetheless, Larsen believes that 2017 is largely a re-set year for CVS Health, and expects the business to return to more robust growth in 2018 and beyond. He reiterates an Outperform rating on CVS Health's shares.
11/09/16
DBAB
11/09/16
NO CHANGE
Target $88
DBAB
Buy
Deutsche still expects Walgreens, Rite Aid deal to close
After speaking to private equity executives, Deutsche Bank analyst George Hill continues to expect Walgreens Boots Alliance's acquisition of Rite Aid (RAD) to be completed. The analyst says the conversations support his belief that most of the divested stores will go to strategic buyers, which he thinks is the FTC preference. Hill has a Buy rating on Walgreens with an $88 price target.
11/08/16
LEER
11/08/16
NO CHANGE
Target $90
LEER
Outperform
Walgreens Boots Alliance price target lowered to $90 from $95 at Leerink
Leerink analyst David Larsen lowered his price target for Walgreens Boots Alliance (WBA) to $90 from $95, noting that he is negatively surprised that Rite Aid (RAD) is expected to add just 5c-12c to 2017 EPS, and also somewhat concerned that 2017 is expected to be a back-half loaded year. Furthermore, the analyst is slightly more cautious on Rite Aid deal's odds, but sees about 65% chance of it closing. Larsen reiterates an Outperform rating on Walgreens Boots Alliance's shares.
SIEGY Siemens
$112.61

-0.24 (-0.21%)

09/07/16
UBSW
09/07/16
DOWNGRADE
UBSW
Neutral
Siemens downgraded to Neutral from Buy at UBS
UBS downgraded Siemens to Neutral saying the risk/reward is not attractive enough at current valuation levels.
05/27/16
JPMS
05/27/16
NO CHANGE
Target $27
JPMS
Underweight
JPMorgan recommends pair trade of long Siemens, short GE
JPMorgan analyst C. Stephen Tusa recommends a Global Industrials pair trade of log Siemens (SIEGY), short General Electric (GE). The analyst has an Underweight rating on GE with a $27 price target and a Neutral rating on Siemens. GE now trades at premium to Siemens while its earnings risk versus consensus will increase over the coming years, Tusa tells investors in a research note.
03/21/16
DBAB
03/21/16
INITIATION
DBAB
Hold
Siemens initiated with a Hold at Deutsche Bank
03/04/16
GSCO
03/04/16
UPGRADE
GSCO
Buy
Siemens upgraded to Buy from Neutral at Goldman
ESRX Express Scripts
$75.88

-0.98 (-1.28%)

11/04/16
DBAB
11/04/16
UPGRADE
Target $70
DBAB
Hold
Express Scripts upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst George Hill last night upgraded Express Scripts (ESRX) to Hold and raised his price target for the shares to $70 from $69. The analyst says he's "increasing confident" that Express "will serve and monetize" the Anthem (ANTM) contract through 2019. The two companies may even 'find their way to a resolution," Hill tells investors in a research note following the company's earnings conference cal. He believes 2017 consensus estimates for Express are likely too low.
11/03/16
DBAB
11/03/16
UPGRADE
DBAB
Hold
Express Scripts upgraded to Hold from Sell at Deutsche Bank
10/27/16
LEER
10/27/16
NO CHANGE
Target $75
LEER
Market Perform
Express Scripts price target lowered to $75 from $80 at Leerink
Leerink analyst David Larsen lowered his price target for Express Scripts (ESRX) to $75 from $80 on stagnant volumes, weakening competitive position, and greater risk to Anthem (ANTM) contract. The analyst reiterates a Market Perform on Express Scripts' shares.
10/28/16
JPMS
10/28/16
NO CHANGE
JPMS
Express Scripts weakness a buying opportunity, says JPMorgan
AGN Allergan
$194.30

1.66 (0.86%)

11/21/16
11/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/16
WBLR
11/21/16
INITIATION
Target $209
WBLR
Market Perform
Allergan initiated with a Market Perform at William Blair
William Blair analyst Tim Lugo started Allergan with a Market Perform rating and $209 price target. The analyst views the company as high quality but sees headwinds in 2017 and 2018. Renewed competition for Botox could weigh on out-year estimates while a Namenda generic could come sooner than expected, Lugo tells investors in a research note.
11/04/16
UBSW
11/04/16
NO CHANGE
Target $240
UBSW
Buy
Allergan price target lowered to $240 from $300 at UBS
UBS analyst Marc Goodman lowered his price target on Allergan to $240 from $300 following disappointing Q3 results and a lowering of his estimates. However, Goodman reiterated his Buy rating on Allergan shares, on the belief it is still a good growth story, has an efficient tax structure and robust pipeline, and has the potential to put up double digit earnings growth for the rest of the decade.
11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Adamas could have positive read through from Allergan deal, says JMP Securities
After Adamas' partner, Allergan (AGN), agreed to buy Chase Pharmaceuticals, JMP Securities analyst Jason Butler thinks that the deal could have positive implications for Adamas Pharmaceuticals and its Alzheimer's treatment, Namzaric, a combination therapy which blocks a neutrotransmitter. The analyst says that the deal "reinforces Allergan's long-term commitment to neurotransmitter focused" Alzheimer;s treatments and provides the opportunity for Chase's drug to be combined with Namzaric. The analyst thinks that such a combined drug could gain additional market share. He keeps a $29 price target and an Outperform rating on Adamas.
IBM IBM
$162.22

-1.31 (-0.80%)

11/10/16
11/10/16
UPGRADE
Target $185

Buy
IBM upgraded to Buy on earnings growth at BofA/Merrill
As previously reported, BofA/Merrill upgraded IBM to Buy from Neutral and raised its price target to $185 from $170. Analyst Wamsi Mohan expects 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. Further, the analyst expects IBM transnational revenues to recovery driven by the mainframe cycle in 2017 and the adoption of a Hybrid cloud model. Mohan said IBM is the most under owned tech named by large-cap US fund managers and provides upside from accumulation.
11/10/16
BOFA
11/10/16
UPGRADE
BOFA
Buy
IBM upgraded to Buy from Neutral at BofA/Merrill
10/18/16
FBCO
10/18/16
NO CHANGE
Target $110
FBCO
Underperform
IBM operational earnings disappoint, says Credit Suisse
Credit Suisse analyst Kulbinder Garcha said IBM reported Q3 earnings came in above expectations but operational earnings were disappointing. The analyst continues to believe 2017 earnings estimates are optimistic and reiterates his Underperform rating and $110 price target on shares.
CELG Celgene
$118.51

-3.62 (-2.96%)

11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
11/28/16
OPCO
11/28/16
INITIATION
Target $141
OPCO
Outperform
Celgene initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Cann initiated Celgene with an Outperform rating and $141 price target, estimating that revenue will grow at a compound annual growth rate of 19% per year for the next five years and that its GAAP EPS can grow by a 31% CAGR over the same span.
11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
11/09/16
STPT
11/09/16
DOWNGRADE
STPT
Hold
Celgene downgraded to Hold from Buy at Standpoint Research
BMY Bristol-Myers
$56.44

0.08 (0.14%)

11/03/16
JPMS
11/03/16
NO CHANGE
JPMS
JPMorgan calls Lilly, Bristol-Myers, Allergan favorite pharma majors
Following a "challenging" Q3 earnings season for the major pharmaceuticals companies, JPMorgan analyst Chris Schott said pricing continues to be a major overhang on the space. However, he believes these and other challenges are "increasingly well reflected" in both earnings and sector multiples and recommends companies early in new product launch cycles. Coming out of the earnings season, Schott named Eli Lilly (LLY), Bristol-Myers (BMY) and Allergan (AGN) as his favorite names in the large-cap pharma space.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.
10/28/16
10/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein saying the stock's valuation now "properly" reflects the challenging fundamental outlook. 2. Bristol-Myers (BMY) upgraded to Long-Term Buy from Neutral at Hilliard Lyons. 3. Qualcomm (QCOM) upgraded on valuation at BMO Capital with analyst Tim Long saying he is neutral on Qualcomm's acquisition of NXP (NXPI), but he expects Qualcomm's stock to stay in a trading range in the wake of the deal. 4. Level 3 (LVTL) upgraded to Outperform from Perform at Oppenheimer with analyst Timothy Horan saying the company has restructured itself in the last few years and now has operational/financial flexibility on free cash flow, with the analyst seeing accelerating growth in 2017. 5. ConocoPhillips (COP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company reported "another solid quarter." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$61.19

-1 (-1.61%)

10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/16
RHCO
10/25/16
NO CHANGE
RHCO
Merck shares should be bought after early FDA approval, says SunTrust
After Merck announced that the FDA had approved the company's Keytruda treatment for the first-line metastatic non-small cell lung cancer with tumor proportion scores of 50% or higher, SunTrust analyst John Boris says that such patients represent about 30% "of the prevalent first-line population." He adds that the approval was earlier than expected and gives Keytruda an approximately 15 month lead over competing drugs in NSCLC. The analyst thinks that the early approval will enable the company's 2021 revenue to beat expectations by a significant amount, and he recommends buying the stock on the news.
10/24/16
RHCO
10/24/16
NO CHANGE
RHCO
Merck Keytruda to have several positive catalysts, says SunTrust
SunTrust analyst John Boris says that several trials of Merck's Keytruda will be stopped early "across multiple tumor types," providing a positive catalyst. Boris says that Keytruda should be approved for 1LNSCLC on or before December 24 and KN-21 chemo combo compendium listing in 1H17. He keeps a $73 price target and Buy rating on Merck.
HUM Humana
$212.64

2.64 (1.26%)

11/21/16
WELS
11/21/16
NO CHANGE
WELS
Humana is best positioned health insurer, says Wells Fargo
Wells Fargo believes that Humana (HUM) is the best positioned health insurer going forward, given Wells' estimate that it obtains 70%+ of its revenue from Medicare Advantage. The firm expects the latter program to be strengthened under the Trump Administration. Wells keeps an Outperform rating on Humana, which has agreed to be acquired by Aetna (AET).
11/15/16
JEFF
11/15/16
NO CHANGE
Target $230
JEFF
Buy
Humana price target raised to $230 from $206 at Jefferies
Jefferies analyst David Windley raised his price target for Humana to $230 after meeting with CFO Brian Kane. The potential to double Medicare Advantage enrollment under a Paul Ryan-type plan "introduces a significant upside scenario," Windley tells investors in a research note. The analyst keeps a Buy rating on the shares.
11/11/16
FBCO
11/11/16
UPGRADE
Target $210
FBCO
Outperform
Humana upgraded to Outperform on Medicare Advantage earnings at Credit Suisse
As previously reported, Credit Suisse upgraded Humana to Outperform from Neutral and raised its price target to $210 from $175. Analyst Scott Fidel said Trump's victory and the Republic sweep will be favorable for Medicare Advantage, adding to Humana's earnings.
11/11/16
11/11/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Equal Weight from Underweight at Barclays with analyst Kannan Venkateshwar saying ESPN is "de-risked" going into 2017 after management quantified the impact of the new NBA contract. 2. Aetna (AET) and Humana (HUM) were upgraded to Outperform from Neutral at Credit Suisse, while the firm upgraded WellCare (WCG) to Neutral from Underperform. 3. Anadarko (APC) and EOG Resources (EOG) were upgraded to Buy from Neutral at Guggenheim. 4. Tiffany (TIF) upgraded to Outperform from Market Perform at Cowen with analyst Oliver Chen saying he believes the luxury market is coming back and Tiffany is well positioned and a trusted brand. 5. Vornado (VNO) upgraded to Buy from Neutral at BofA/Merrill with analyst James Feldman saying he believes the decision to spin DC and partner with JBG will allow management to focus on the New York City platform and notes the Penn Plaza corridor is rapidly improving. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MYL Mylan
$36.61

0.55 (1.53%)

10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/10/16
10/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/26/16
10/26/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mylan (MYL) initiated with a Buy at Mizuho. 2. Five Below (FIVE) initiated with a Buy at Longbow. 3. NetSuite (N) reinstated with an Underperform at BofA/Merrill. 4. Adient (ADNT) initiated with a Buy at Northcoast. 5. Party City (PRTY) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/16
MZHO
10/25/16
INITIATION
Target $49
MZHO
Buy
Mylan initiated with a Buy at Mizuho
Mizuho analyst Irina Koffler initiated Mylan with a Buy and a $49 price target.
UTHR United Therapeutics
$125.61

-0.96 (-0.76%)

10/28/16
LEER
10/28/16
NO CHANGE
Target $127
LEER
Market Perform
United Therapeutics price target raised to $127 from $121 at Leerink
Leerink analyst Joseph Schwartz raised his price target for United Therapeutics to $127 from $121 following the company's revenue beat, and to reflect the impact of ongoing share buybacks. The analyst reiterates a Market Perform rating on the shares.
11/29/16
LEHM
11/29/16
DOWNGRADE
Target $100
LEHM
Underweight
United Therapeutics downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham downgraded United Therapeutics to Underweight and lowered its price target to $100 from $116 due to a more negative view of the PAH franchise. Following physician conversations, the analyst has a more negative view of Orenitram's prospects given physicians preference for Actelion's Uptravi and is more bearish on IV/injectable Remodulin given delays in getting the drug/combo approved.
11/07/16
HCWC
11/07/16
INITIATION
Target $10
HCWC
Buy
SteadyMed initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started SteadyMed (STDY) with a Buy rating and $10 price target. The company's disposable treprostinil pump offers an "atypical biotech investment opportunity," Fein tells investors in a research note. He sees a "high likelihood" for a ruling in favor of SteadyMed by next spring in the company's legal challenge of a United Therapeutics' (UTHR) key treprostinil patent.
10/28/16
LTCO
10/28/16
UPGRADE
Target $138
LTCO
Buy
United Therapeutics upgraded to Buy from Neutral at Ladenburg
Ladenburg Thalmann analyst Matt Kaplan upgraded United Therapeutics to Buy citing the company's continued pipeline progress following its Q3 results. The analyst upped his price target for the shares to $138 from $128.
PHG Philips
$28.61

-0.52 (-1.79%)

10/26/16
10/26/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Time Warner (TWX) upgraded to Overweight from Equal Weight at Barclays with analyst Kannan Venkateshwar saying AT&T (T) has a "number of ways" to deal with regulatory concerns over the merger. 2. Procter & Gamble upgraded to Outperform from Underperform at CLSA with analyst Caroline Levy saying she believes P&G is positioned long-term growth as benefits of six years of efficiency projects continue to yield savings and scale. 3. Transocean upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Ole Slorer saying Transocean is executing on cost controls resulting in positive Earnings Before Interest, Tax, Depreciation and Amortization accretion of $600M in 2016 alone and sees an improved 2019 liquidity position as a result. 4. Philips (PHG) upgraded to Buy from Hold at HSBC with analyst Jan Keppeler citing the company's recovering margins. 5. Baker Hughes (BHI) upgraded to Outperform from Market Perform at Cowen with analyst Marc Bianchi saying cost cutting execution has been impressive with a total of $1B in savings, compared to guidance of $650M by year end 2016, and sees more to come. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/16
WEDB
11/07/16
NO CHANGE
Target $67
WEDB
Outperform
Masimo price target raised to $67 from $63 at Wedbush
Wedbush analyst Tao Levy raised his price target on Masimo (MASI) to $67 from $63, saying the multi-year business partnership announced with Philips (PHG) is a positive. The analyst keeps an Outperform rating on Masimo shares.
11/23/16
11/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Philips (PHG) initiated with a Buy at Citi. 2. Rockwell Collins (COL) initiated with an Outperform at Wolfe Research. 3. Golar LNG (GLNG) assumed with a Buy at Seaport Global. 4. Cincinnati Bell (CBB) initiated with a Buy at Drexel Hamilton. 5. ZTO Express (ZTO) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/23/16
SBSH
11/23/16
INITIATION
SBSH
Buy
Philips initiated with a Buy at Citi
Price target EUR 32.
AXON Axovant Sciences
$13.53

-0.17 (-1.24%)

11/25/16
BARD
11/25/16
NO CHANGE
Target $29
BARD
Outperform
Lilly trial failure has little to do with Axovant Sciences, says Baird
Baird analyst Brian Skorney said Eli Lilly's (LLY) solanezumab drug trial failure has little to do with Axovant Sciences (AXON) drug trial for Alzheimer's. The analyst said Lilly's failure is a reminder of the difficulty of the disease, but the two company's drugs are very different and meant to have very different effects. Skorney reiterated his Outperform rating and $29 price target on Axovant shares.
11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Axovant not impacted by Lilly's solanezumab failure, says JMP Securities
JMP Securities analyst Jason Butler said Axovant Sciences (AXON) is not impacted by Eli Lilly's (LLY) solanezumab. The analyst said solanezumab has a very different mechanism of action, and unlike solanezumab, Axovant's has already prospectively demonstrated statistically significant improvements in cognition and function in a pivotal trial. Butler recommends buying Axovant on weakness and reiterates his Outperform rating and $36 price target.
11/23/16
BARD
11/23/16
NO CHANGE
BARD
Axovant Sciences outlook unchanged on Lilly's solanezumab failure, says Baird
09/23/16
PIPR
09/23/16
NO CHANGE
Target $32
PIPR
Overweight
Axovant Sciences selloff provides entry point, says Piper Jaffray
Piper Jaffray analyst Charles Duncan believes yesterday's selloff in shares of Axovant Sciences provides an entry point into the name. Lundbeck's announcement that its first Phase III data with idalopirdine in Alzheimer's missed the primary endpoint does not have predictive value for the Axovant's ongoing RVT-101 Phase III study, Duncan tells investors in a research note. The analyst sees "several key differences" between the two candidates and Phase III programs. He believes RVT-101 is the best-in-class 5-HT6 candidate and thinks its MINDSET trial is well designed to show clinical benefit. Duncan reiterates an Overweight rating on Axovant with a $32 price target.
GILD Gilead
$73.70

-1.17 (-1.56%)

11/17/16
LEER
11/17/16
NO CHANGE
Target $89
LEER
Market Perform
Gilead myelofibrosis data miss may open path for M&A, says Leerink
Leerink analyst Geoffrey Porges notes that Gilead (GILD) released disappointing Phase III data for its JAK 1/2 inhibitor momelotinib in myelofibrosis. The company indicated that they plan to discuss these results with regulatory authorities to determine the next steps, but it seems likely that momelotinib will be written off, he adds. However, Porges believes that this disappointment restores Incyte (INCY) to the list of feasible candidates for acquisition by Gilead, since it would no longer face the obligation to divest one of the overlapping JAK programs. He reiterates a Market Perform rating and $89 price target on Gilead's shares.
11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.
PFE Pfizer
$32.14

0.22 (0.69%)

11/02/16
11/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Hold from Buy at Argus and to Market Perform from Outperform at BMO Capital. 2. BP (BP) downgraded to Hold from Buy at Societe Generale. 3. Corning (GLW) downgraded to Buy from Conviction Buy at Goldman with analyst Doug Clark saying the restocking phase of glass/TV cyclical recovery is now "well understood and largely behind us." 4. Adeptus Health (ADPT) downgraded to Underperform from Buy at BofA/Merrill, to Hold from Buy at Jefferies, and to Equal Weight from Overweight at Stephens. 5. Brookdale Senior Living (BKD) downgraded to Underperform from Neutral at BofA/Merrill, to Market Perform from Outperform at Wells Fargo, and to Outperform from Top Pick at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/16
11/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying he sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders. 2. Comerica (CMA) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Tractor Supply (TSCO) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying he expects the company to benefit from colder weather and the improving US economy and said product assortments and promotions have also been adjusted to the new economics of the energy patch and its impact on this company's customers. 4. Del Frisco's (DFRG) upgraded to Outperform from Neutral at Credit Suisse with analyst Jason West saying it is a key beneficiary of improved high-end consumer and corporate spending. 5. Veracyte upgraded to Buy from Neutral at Janney Capital with analyst Paul Knight saying the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/16
ARGS
11/02/16
DOWNGRADE
ARGS
Hold
Pfizer downgradedon weaker outlook at Argus
As noted earlier, Argus downgraded Pfizer to Hold from Buy. Analyst Jacob Kilstein cited "recent pipeline setbacks, prospects for increased competition, and management's decision to shelve its business separation plan" as reasons for the downgrade.
11/29/16
LEHM
11/29/16
UPGRADE
Target $38
LEHM
Overweight
Pfizer upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Pfizer to Overweight and raised its price target to $38 from $37. Meacham sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders.
LLY Eli Lilly
$67.12

-0.03 (-0.04%)

11/25/16
ATLE
11/25/16
DOWNGRADE
ATLE
Neutral
Eli Lilly downgraded to Neutral from Overweight at Atlantic Equities
11/28/16
MAXM
11/28/16
NO CHANGE
Target $15
MAXM
Buy
Anavex may be targeting 'ideal approach' to Alzheimer's disease, says Maxim
After Eli Lilly's (LLY) solanezumab failed its third Phase 3 study in early-stage Alzheimer's disease, Maxim analyst Jason McCarthy noted that Anavex's (AVXL) 2-73 targets the disease "more broadly upstream" to restore proper CNS cell function and has shown "promising early data." While too soon to draw any firm conclusions, given the lessons learned from failures in pursuit of other avenues, Anavex "may be on the right track" by looking upstream, said McCarthy, who keeps a Buy rating and $15 price target on the stock.
11/28/16
BOFA
11/28/16
NO CHANGE
BOFA
Buy
Eli Lilly removed from US 1 List at BofA/Merrill
REGN Regeneron
$379.24

-8.02 (-2.07%)

11/07/16
LEER
11/07/16
NO CHANGE
Target $504
LEER
Outperform
Regeneron price target lowered to $504 from $513 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Regeneron (REGN) to $504 from $513 on valuation. Porges expects near-term volatility for the stock given questions regarding the upcoming second interim analysis of the Odyssey Outcomes trial for Praluent, the restart of trials for pain treatment fasinumab after the FDA's clinical hold, and the issues regarding development partner Sanofi's (SNY) fill-finish plant leading to sarilumab's Complete Response Letter last week. He reiterates an Outperform on Regeneron's shares.
11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Piper sees Biotech rally continuing into 2017, lays out five to own
Piper Jaffray analyst Edward Tenthoff expects the rally in Biotechs, following "the trifecta" of a Trump Presidential election, Republican Congress sweep and defeat of Prop 61 in California, to continue into 2017. He recommends focusing on shares of Vertex (VRTX), Regeneron (REGN), Alnylam (ALNY), Exelixis (EXEL) and OncoMed (OMED). Tenthoff has a Neutral rating on Regeneron and Overweight ratings on the other four names.
11/29/16
RHCO
11/29/16
NO CHANGE
RHCO
Ophthotech has no read through from competitor failure, says SunTrust
After Regeneron's (REGN) REGN2176-3 for wet AMD failed to show significant efficacy in a Phase II trial, SunTrust analyst Yatin Suneja does not believe that the failure bodes badly for Ophthotech (OPHT) whose Fovista treatment, like Regeneron's (REGN) drug, utilizes the PDGF pathway. The analyst says that Ophthotech's Fovista "has shown impressive efficacy in both Phase I and Phase IIb studies," and Suneja expects Fovista's Phase III results to also show strong efficacy. The analyst reiterates a $100 price target and a Buy rating on Ophthotech.

TODAY'S FREE FLY STORIES

KTOV

Kitov Pharmaceuticals

$3.44

0.05 (1.47%)

09:27
12/07/16
12/07
09:27
12/07/16
09:27
Hot Stocks
Kitov Pharmaceuticals completes all KIT-302 testing to file NDA »

Kitov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNCFF

UniCredit

$2.47

0.28 (12.79%)

09:25
12/07/16
12/07
09:25
12/07/16
09:25
Periodicals
Pioneer suspends a pair of senior Dublin execs, Irish Times reports »

UniCredit's Pioneer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARIA

ARIAD

$13.69

0.41 (3.09%)

09:25
12/07/16
12/07
09:25
12/07/16
09:25
Conference/Events
ARIAD to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 29

    Apr

OCLR

Oclaro

$8.35

-0.05 (-0.60%)

09:25
12/07/16
12/07
09:25
12/07/16
09:25
Conference/Events
Oclaro participates in a conference call with Jefferies »

Conference call with CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

09:24
12/07/16
12/07
09:24
12/07/16
09:24
Hot Stocks
Starbucks says sees at-home coffee sales growth slowing »

Cites fewer Keurig sales.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

WDC

Western Digital

$63.85

1.76 (2.83%)

, SQ

Square

09:23
12/07/16
12/07
09:23
12/07/16
09:23
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Anthera…

WDC

Western Digital

$63.85

1.76 (2.83%)

SQ

Square

AAPL

Apple

$109.95

0.84 (0.77%)

PLAY

Dave & Buster's

$48.00

-0.83 (-1.70%)

VRA

Vera Bradley

$14.67

-0.07 (-0.47%)

ANTH

Anthera

$1.47

-0.03 (-2.00%)

SIGM

Sigma Designs

$7.75

0.1 (1.31%)

SSNLF

Samsung

AVAV

AeroVironment

$29.34

0.76 (2.66%)

OXM

Oxford Industries

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 14

    Dec

  • 09

    Jan

  • 09

    Jan

  • 13

    Mar

WDAY

Workday

09:23
12/07/16
12/07
09:23
12/07/16
09:23
Downgrade
Workday rating change  »

Workday downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

AAPL

Apple

$109.95

0.84 (0.77%)

, GOOG

Alphabet

$759.11

-3.41 (-0.45%)

09:21
12/07/16
12/07
09:21
12/07/16
09:21
Hot Stocks
Kantar says Apple iOS share gains driven by iPhone 7 sales »

Kantar Worldpanel ComTech…

AAPL

Apple

$109.95

0.84 (0.77%)

GOOG

Alphabet

$759.11

-3.41 (-0.45%)

GOOGL

Alphabet Class A

$776.18

-2.04 (-0.26%)

MSFT

Microsoft

$59.95

-0.27 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

  • 13

    Mar

AZO

AutoZone

09:20
12/07/16
12/07
09:20
12/07/16
09:20
Recommendations
AutoZone analyst commentary  »

AutoZone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

AAPL

Apple

$109.95

0.84 (0.77%)

09:18
12/07/16
12/07
09:18
12/07/16
09:18
Downgrade
Apple rating change  »

Apple downgraded to Mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

09:18
12/07/16
12/07
09:18
12/07/16
09:18
Hot Stocks
Starbucks says five-year goal is to 'elevate the brand' »

Also says goal is to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

NBR

Nabors Industries

09:16
12/07/16
12/07
09:16
12/07/16
09:16
Downgrade
Nabors Industries rating change  »

Nabors Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

09:16
12/07/16
12/07
09:16
12/07/16
09:16
Hot Stocks
Fitbit acquires certain assets from Pebble, deal excludes hardware products »

Fitbit announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AVAV

AeroVironment

$29.34

0.76 (2.66%)

09:15
12/07/16
12/07
09:15
12/07/16
09:15
Hot Stocks
AeroVironment, Cal State Fresno to research water stress in almond trees »

AeroVironment announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:15
12/07/16
12/07
09:15
12/07/16
09:15
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

CLB

Core Laboratories

09:13
12/07/16
12/07
09:13
12/07/16
09:13
Downgrade
Core Laboratories rating change  »

Core Laboratories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ETFC

E-Trade

$35.52

0.31 (0.88%)

09:11
12/07/16
12/07
09:11
12/07/16
09:11
Hot Stocks
E-Trade CEO says running to grow company, not sell it »

Says running a company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

09:09
12/07/16
12/07
09:09
12/07/16
09:09
Hot Stocks
Breaking Hot Stocks news story on Starbucks »

Starbucks says sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

S

Sprint

$8.17

0.12 (1.49%)

09:08
12/07/16
12/07
09:08
12/07/16
09:08
Hot Stocks
Sprint becomes first U.S. Pokemon GO partner »

Sprint and Niantic,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 04

    Jan

RES

RPC, Inc.

$21.39

-0.24 (-1.11%)

09:08
12/07/16
12/07
09:08
12/07/16
09:08
Downgrade
RPC, Inc. rating change  »

RPC, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:07
12/07/16
12/07
09:07
12/07/16
09:07
Conference/Events
Cowen analysts hold an analyst/industry conference call »

Analysts hold an…

HBAN

Huntington Bancshares

$13.22

0.19 (1.46%)

09:07
12/07/16
12/07
09:07
12/07/16
09:07
Hot Stocks
Huntington Bancshares sees FY17 revenue growth of 20%+ »

Says implementation of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

OCRX

Ocera Therapeutics

$2.35

0.1 (4.44%)

09:05
12/07/16
12/07
09:05
12/07/16
09:05
Hot Stocks
Ocera Therapeutics completes enrollment in STOP-HE Phase 2b study »

Ocera Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIGM

Sigma Designs

$7.75

0.1 (1.31%)

09:05
12/07/16
12/07
09:05
12/07/16
09:05
Downgrade
Sigma Designs rating change  »

Sigma Designs downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

SLM

Sallie Mae

$10.78

0.23 (2.18%)

09:05
12/07/16
12/07
09:05
12/07/16
09:05
Recommendations
Sallie Mae analyst commentary  »

Sallie Mae price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.